title: Extramedullary progression of multiple myeloma following GM-CSF treatment--grounds for caution?
authors.forename: F
authors.initials: F
authors.lastname: Celsing
authors.forename: R
authors.initials: R
authors.lastname: Hast
authors.forename: L
authors.initials: L
authors.lastname: Stenke
authors.forename: H
authors.initials: H
authors.lastname: Hansson
authors.forename: P
authors.initials: P
authors.lastname: Pisa
mesh_terms: D016207:Cytokines / Q000097:blood; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D009362:Neoplasm Metastasis; D011241:Prednisone / Q000627:therapeutic use
chemical_list: D016207:Cytokines; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D008558:Melphalan; D011241:Prednisone